These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12544772)

  • 1. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
    Deitcher SR; Fesen MR; Kiproff PM; Hill PA; Li X; McCluskey ER; Semba CP;
    J Clin Oncol; 2002 Jan; 20(1):317-24. PubMed ID: 11773185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
    Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
    J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
    Ng R; Li X; Tu T; Semba CP
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer.
    Liu CY; Jain V; Shields AF; Heilbrun LK
    J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):39-44. PubMed ID: 14709685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
    Terrill KR; Lemons RS; Goldsby RE
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
    Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
    Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.
    Gabrail N; Sandler E; Charu V; Anas N; Lim E; Blaney M; Ashby M; Gillespie BS; Begelman SM
    J Vasc Interv Radiol; 2010 Dec; 21(12):1852-8. PubMed ID: 21111365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III, open-label, single-arm study of tenecteplase for restoration of function in dysfunctional central venous catheters.
    Tebbi C; Costanzi J; Shulman R; Dreisbach L; Jacobs BR; Blaney M; Ashby M; Gillespie BS; Begelman SM
    J Vasc Interv Radiol; 2011 Aug; 22(8):1117-23. PubMed ID: 21570873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
    Chesler L; Feusner JH
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):653-6. PubMed ID: 12439038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
    Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
    Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
    Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
    J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices.
    Davis SN; Vermeulen L; Banton J; Schwartz BS; Williams EC
    Am J Health Syst Pharm; 2000 Jun; 57(11):1039-45. PubMed ID: 10876745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.